CC-AMC Pilot Awards in HIV-Associated Malignancies
Project award amount: Awards of up to $50,000 are encouraged, but up to $100,000 may be requested
The focus of the awards program is to stimulate research collaborations on HIV-associated malignancies between investigators at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) and NCI-supported AIDS Malignancy Consortium (AMC) investigators at UCSF by providing pilot funding to junior HDFCCC investigators new to HIV-related malignancies research. Malignancies constitute a substantial source of morbidity and mortality among HIV-infected persons, even in the era of anti-retroviral therapy. AIDS-defining malignancies (Kaposi’s sarcoma, non-Hodgkins lymphoma, cervical cancer) continue to develop in HIV-infected persons, particularly in developing countries, and the incidence of non-AIDS defining malignancies is growing among HIV-infected men and women
Funding is available through the HFDCCC to foster the development of the next generation of researchers working in the field of HIV-related malignancies. The HDFCCC will support pilot projects focused on (a) developing new lines of investigation to support development of new AMC protocols; (b) developing new approaches to understanding the molecular pathogenesis of HIV malignancies; and (c) more effectively exploiting HDFCCC expertise and facilities, to maximize the scientific productivity and correlative science of AMC protocols. Examples of research topics include:
- Role of inflammation in cancer development in HIV-infected patients
- Predictors of survival in patients with AIDS-defining and non-AIDS defining cancer, nationally and internationally
- Role of oncogenic viruses and/or HIV in the induction of HIV-associated malignancies
- Impact of prolonged immunosuppression on the development of HIV-associated malignancies
- Impact of incomplete or failed responses to HAART on the development of HIV-associated malignancies
- Host genetic susceptibility to HIV-associated malignancies in patients with HIV infection.
- Strategies for the prevention of cancer in the HIV-positive population
Proposals considered responsive to this request for applications will be those that focus on maximizing the scientific productivity and correlative science of existing AMC protocols, or establishing novel lines of investigation that may lead to the development of new AMC protocols.
CC-AMC Pilot awards seek to provide opportunities to junior scientists to obtain the requisite mentored research experience and training to compete for career-development funds. Project proposals should be geared toward the interests of the applicant (clinical, basic, and/or behavioral-epidemiological research) and focus on topics relevant to the CC and AMC mission. Applicants for this award must identify BOTH CC AND AMC faculty research mentors who will commit to guiding the applicant through the duration of the proposed project.
Note: Studies involving clinical trials are not allowed
- The award level for this program is up to $100,000 in total costs (may include personnel salary and benefits). Awards of up to $50,000 in total costs are encouraged, but up to $100,000 in total costs may be requested.
- The number of grants awarded is determined by funding available
- The funding will last for a one-year period.
- Any carry forward of funding will require approval and must be fully justified
- Progress reports will be due to the HDFCCC Programs Office at the midpoint and at the end of the project period. Reports should reference subsequent funding acquired, research goals met, posters, publications, etc.
- Awardees will be strongly encouraged to participate in the UCSF HIV-related Malignancies Research Group (HMRG) and the Andy I. Choi Mentoring Program of the UCSF-GIVI Center for AIDS Research. The HMRG is part of the HDFCCC Cancer, Immunity, and Microenvironment Program and awardees are also strongly encouraged to participate in this program’s activities.
- If applicable, CHR and IACUC approval and must be obtained before funding will be released to the awardee.
- This award does not support travel or equipment.
- Studies involving clinical trial trials are not allowed.
Eligibility: Full-time faculty of UCSF (academic appointment in the Professorial, In-Residence, Clinical X, Clinical, Adjunct, and Professional Research series), excluding faculty without pay, are eligible. Specialists and post-doctoral fellows are not eligible.
Investigators must be a member of the HDFCCC. A list of HDFCCC Members and Associate Members and membership application information can be found at http://cancer.ucsf.edu/people/membership/.
An AMC member must serve as a co-investigator on the pilot project application.
Criteria for Review and Evaluation of Applications: Applications that are complete and meet eligibility requirements will be evaluated for scientific and technical merit by an appropriate review committee convened by the UCSF Resource Allocation Program in accordance with the review criteria employed by the NIH which include five core areas: 1. Significance, 2. Approach, 3. Innovation, 4. Investigator, 5. Environment. Each of these criteria will be addressed and considered in assigning the overall score weighing them as appropriate for each application.
For information about the AIDS Malignancy Consortium program:
Joel Palefsky M.D. (HPV-related malignancies, non-AIDS-defining malignancies): email@example.com
Lawrence Kaplan, M.D. (Lymphoma): firstname.lastname@example.org
Toby Maurer, M.D. (Kaposi's sarcoma): email@example.com
For information about the Helen Diller Family Comprehensive Cancer Center:
The CFAR Andy I. Choi Mentoring Program:
For a list of Cancer Center faculty:
For information on the Cancer Center’s Cancer, Immunity and the Microenvironment Program:
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco